Inhalation & Respiratory Drug Delivery 2019

DESCRIPTION

On 30 & 31 May 2019, New York (USA) will host the BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 conference. This year’s event is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market. The agenda also features key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy.

Over 100+ delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will be joining the Inhalation & Respiratory Drug Delivery 2019

The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.

Over 20+ presentations and case studies focused on the key issues in inhalation and respiratory drug delivery. Join us at the Inhalation & Respiratory Drug Delivery 2019 in New York

The BioTech Pharma Summit: Inhalation & Respiratory Drug Delivery 2019 will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis.

KEY PRACTICAL LEARNING POINTS

  • Novel technologies for pulmonary & nasal delivery
  • Innovative development of inhalation devices
  • Digital health combination products
  • Analytical tools for inhaled medicines
  • Challenges of bringing inhalation and respiratory drug delivery products to market
  • Regulatory updates in the global respiratory market
  • The challenges of developing inhalation devices
  • Alternative therapeutic fields
  • Dry-powder inhalers (DPIs) and Metered-dose inhalers (MDIs)
  • Routes to controlling aerosol response
  • Characterizing aerosol dynamics
  • Model validation
  • Future directions in inhalation and respiratory drug delivery research
  • Regulatory pathways for inhaled therapies
  • Challenges of developing a generic inhaled product

WHO SHOULD ATTEND?

The BioTech Pharma Summit (EPM Group) are exclusive events consisting of world-class keynote addresses and presentations designed specifically for senior level attendees from research & academic institutions, clinical research institutions and hospital laboratories as well as major pharmaceutical and biotech companies based Worldwide. Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

  • Respiratory Drug Development
  • Generics & Respiratory
  • Inhalation Drug Delivery Technologies
  • Device Development and Engineering
  • Respiratory Pharmacology
  • Medical Devices & Injectors
  • Inhalation Device Development
  • Inhaled Formulation Science
  • Inhalation Product Development
  • Respiratory Regulations
  • Generics & Respiratory
  • Inhalation Process Development
  • Respiratory Medicine
  • Inhalation Drug Delivery
  • E-Health
  • Inhaled Dosage Forms
  • Outsourcing
  • Process Development
  • Respiratory Pharmacology
  • Device Engineering
  • Drug Delivery Innovation
  • Inhalation Devices
  • Metered Dose Inhaler Development
  • Medical Marketing
  • Respiratory R&D
  • Particle Characterisation
  • Business Development
  • New Delivery Technologies
  • Connective Health
  • Respiratory Regulations
  • Pulmonary Disease
  • Inhalation
  • Scientific Research

*For Group registration or Sponsorship/Exhibition enquires, please use the contact form below.

CEO at FLUIDDA, US
Programme Manager at Vectura Group plc, DE
Director, Scientific Affairs at Eurofins BioPharma Product Testing, US
Associate Director, Regulatory Affairs, Combination Products at Teva Pharm, US
Professor of Pharmaceutics at Virginia Commonwealth University School of Pharmacy, US
Director of Respiratory Care Services at Stanford University Medical Center, US
Scientific Business Development Manager at ACG, US
Chairman & CSO at Dance Biopharm, US
Director, Center for Digital Health at Icahn School of Medicine at Mount Sinai, US
Sr. Study Director at Nelson Labs, BE
CEO, KAER Biotherapeutics Corporation, US
Director at Takeda Pharmaceutical Company, US
Director, Corporate Business Integration at Aptar Pharma, US
Manager: Inhalation Technology at Battelle, US
Professor at University of Florida, US
Executive Vice President of R&D and Chief Scientific Officer at Noveome Biotherapeutics, US
Doc. Package
650
Buy Ticket

Get all the IRDD Summit presentations


Event Details
Sponsors